Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 8/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.33 |
| ▸ | RBP1 | P09455 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25258144 | 0.88 | PDE2A (0.36) | PDE2AMEN1KMT2AHTTPTPRZ1 | |
| SCHEMBL30304210 | 0.88 | PDE2A (0.36) | PDE2AMEN1KMT2AHTTPTPRZ1 | |
| SCHEMBL23578311 | 0.86 | MEN1 (0.35) | PDE2AMEN1KMT2AHTTPTPRZ1 | |
| SCHEMBL23578231 | 0.86 | MEN1 (0.37) | PDE2AMEN1KMT2AHTTALOX5AP | |
| SCHEMBL30304246 | 0.86 | PDE2A (0.36) | PDE2AMEN1KMT2AHTTPTPRZ1 | |
| SCHEMBL25801896 | 0.85 | KMT2A (0.37) | PDE2AMEN1KMT2AHTTALOX5AP | |
| SCHEMBL23588185 | 0.85 | KMT2A (0.39) | MEN1KMT2AHTTALOX5APLMNA | |
| SCHEMBL25805322 | 0.84 | KMT2A (0.40) | MEN1KMT2AHTTALOX5APLMNA | |
| SCHEMBL23578057 | 0.83 | KMT2A (0.36) | MEN1KMT2AHTTALOX5APLMNA | |
| SCHEMBL23578431 | 0.83 | S1PR1 (0.39) | PDE2AMEN1KMT2AHTTALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081511-B1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2024-07-31 | — | — | EP | claimed |
| CN-115066418-A | Carboxy derivatives with anti-inflammatory properties | 西特瑞治疗有限公司 | 2022-09-16 | — | — | CN | claimed |
| EP-4081511-B3 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LTD (GB) | 2026-03-04 | — | — | EP | disclosed |
| EP-4359390-A1 | ACRYLAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | Sitryx Therapeutics Limited (GB) | 2024-05-01 | — | — | EP | disclosed |
| US-20240018111-A1 | ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2024-01-18 | — | — | US | disclosed |
| US-20240018111-A1 | ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2024-01-18 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| EP-4192821-A1 | ALPHA,BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022269251-A1 | ACRYLAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | SITRYX THERAPEUTICS LIMITED (GB) | 2022-12-29 | — | — | WO | disclosed |
| EP-4081511-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2022-11-02 | — | — | EP | disclosed |
| CN-115066418-A | Carboxy derivatives with anti-inflammatory properties | 西特瑞治疗有限公司 | 2022-09-16 | — | — | CN | disclosed |
| WO-2021130492-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | PDE2A 897/4885MEN1 4504/4885KMT2A 3125/4885 |
| US-20240018111-A1 | ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES | PTGS1, PTGER1, PTGES2 | PDE2A 772/4885MEN1 2557/4885KMT2A 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.